$70.78
0.76% yesterday
Nasdaq, Nov 12, 10:00 pm CET
ISIN
US6047491013
Symbol
MIRM

Mirum Pharmaceuticals Inc Stock price

$70.78
-1.39 1.93% 1M
+25.21 55.32% 6M
+29.43 71.17% YTD
+28.50 67.41% 1Y
+51.55 268.07% 3Y
+52.68 291.05% 5Y
+57.57 435.81% 10Y
+57.57 435.81% 20Y
Nasdaq, Closing price Wed, Nov 12 2025
-0.54 0.76%
ISIN
US6047491013
Symbol
MIRM
Industry

Key metrics

Basic
Market capitalization
$3.6b
Enterprise Value
$3.6b
Net debt
$4.5m
Cash
$304.6m
Shares outstanding
50.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
8.5 | 7.1
EV/Sales
8.5 | 7.1
EV/FCF
negative
P/B
14.3
Financial Health
Equity Ratio
33.7%
Return on Equity
-38.9%
ROCE
-9.8%
ROIC
-
Debt/Equity
1.2
Financials (TTM | estimate)
Revenue
$429.2m | $515.9m
EBITDA
$-33.0m | $-18.2m
EBIT
$-57.0m | $-35.0m
Net Income
$-58.9m | $-34.8m
Free Cash Flow
$-1.2m
Growth (TTM | estimate)
Revenue
62.3% | 53.1%
EBITDA
62.5% | 71.5%
EBIT
47.3% | 60.1%
Net Income
46.3% | 60.4%
Free Cash Flow
97.1%
Margin (TTM | estimate)
Gross
79.0%
EBITDA
-7.7% | -3.5%
EBIT
-13.3%
Net
-13.7% | -6.8%
Free Cash Flow
-0.3%
More
EPS
$-1.2
FCF per Share
$0.0
Short interest
13.7%
Employees
322
Rev per Employee
$1.1m
Show more

Is Mirum Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

Mirum Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Mirum Pharmaceuticals Inc forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a Mirum Pharmaceuticals Inc forecast:

Buy
94%
Hold
6%

Financial data from Mirum Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
429 429
62% 62%
100%
- Direct Costs 90 90
23% 23%
21%
339 339
77% 77%
79%
- Selling and Administrative Expenses 229 229
29% 29%
53%
- Research and Development Expense 168 168
38% 38%
39%
-33 -33
63% 63%
-8%
- Depreciation and Amortization 24 24
19% 19%
6%
EBIT (Operating Income) EBIT -57 -57
47% 47%
-13%
Net Profit -59 -59
46% 46%
-14%

In millions USD.

Don't miss a Thing! We will send you all news about Mirum Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mirum Pharmaceuticals Inc Stock News

Neutral
Business Wire
2 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Neutral
Business Wire
6 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharma Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD's The Liver Meeting®.
Neutral
Seeking Alpha
8 days ago
Mirum Pharmaceuticals, Inc. ( MIRM ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Christopher Peetz - CEO & Director Peter Radovich - COO & President Joanne M. Quan - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Abdulqudus Tahlil - JPMorgan Ch...
More Mirum Pharmaceuticals Inc News

Company Profile

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.

Head office United States
CEO Christopher Peetz
Employees 322
Founded 2018
Website mirumpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today